Presented at ASM Microbe, Pelumi Oladipo's study identifies the first North American human case of E marmotae infection and introduces methods to improve species-level diagnosis.
First author Jacek Skarbinski, MD, offers insights on new data published last week showing how this population can benefit from continued vaccination.
The most successful FMT approach involved administering multiple-dose capsules or colonoscopy following an extended course of antibiotic pretreatment.
Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP) talks about how his team developed a test to identify fungi, and how they utilize it to diagnose, make treatment adjustments, and rule out hospital acquired infections.
Jason Haukoos, MD, on how the DETECT Hep C trial leverages 24/7 emergency care to reach vulnerable patients.
Margie Lee, DVM, MS, PhD, wants young researchers and providers to know that despite the current environment, this is not the first time science has had to deal with a challenges to research and funding.
Edward Weinstein, MD of Pfizer, says longer courses may benefit severely immunocompromised patients, even without major gains in viral suppression.
Cases and deaths in the state are down from the 2 previous years. Here are some clinical considerations, treatment options, and prevention strategies in relation to these infections.
This week, the first US study screening hepatitis B and D concurrently found that 2.2% of HBV-positive samples had HDV antibodies, the FDA approved GSK’s Shingrix, and more.
Luisa M Stamm, MD, PhD, further discusses MK-8527 and islatravir-based regimens in HIV research.
In the second installment of our conversation with Jeremy Faust, MD, he addresses the uncertainty surrounding guidance and where to turn for information.
New evidence-based recommendations prioritize timely, targeted therapy and a symptom-focused classification to optimize treatment outcomes and antimicrobial stewardship.
At IAS 2025, ViiV’s Jean van Wyk, MBChB, MFPM, shares how real-world data and patient priorities are guiding a new era of HIV care.
A large study looked at booster uptake and effectiveness among US adults who received chemotherapy or immunotherapy.
New format eliminates reconstitution step, offering greater convenience for providers and supporting expanded access for at-risk adults.
New research finds no link between aluminum in vaccines and autism, asthma, or other health conditions, strengthening the case for vaccine safety.
Jeremy Faust, MD, discusses what he and other providers are dealing with in the face of conflicting guidance and actions from the federal agencies.
Jason Haukoos, MD, MSc, FACEP, shares the decade-long journey behind the DETECT Hep C trial and why emergency departments are key to implementing Centers for Disease Control and Prevention screening guidelines.
The designation is for the company’s TXA14007, its investigational antibiotic to be studied in combination with levofloxacin.
Analysis by Carly Ching, PhD, reveals that global AMR policies overemphasize human health while neglecting farmer-focused messaging that could improve adoption and impact.
In our latest podcast, first author Elizabeth Marlowe, PhD, D(ABMM), offers insights on her study looking at this ongoing issue, including the need for increased testing and getting patients into the continuum of care in a more efficient manner.
At IAS 2025, Luisa Stamm, MD, PhD, explains the NRTTI’s mechanism, study setup, and key data on HIV prevention efforts.
TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae.
At IAS 2025, the VOLITION and OPERA study data show patient preference and real-world use of injectable CAB + RPV LA, informing the treatment strategy of ViiV CMO Jean van Wyk.
Yale School of Medicine’s Department of Pathology has embraced the booming field of digital pathology, where digital scanners and AI are improving speed and accuracy.
Study findings underscore the cost-effectiveness of more frequent hepatitis C testing among people who inject drugs, compared to less frequent or no testing at all.
Shortening the OraQuick HCV antibody test from 20 to 5 minutes reduced false positives and unnecessary follow-up RNA testing, but detected fewer viremic individuals.
This week, a mother's struggle with C difficile during pregnancy, racial disparities in COVID-19 treatment, Supreme Court decision preserving access to HIV prevention, and more.
The company said it expects to have its updated mRNA-1273 (Spikevax) vaccine available for these eligible populations in the US for the next respiratory virus season.
